RedHill Biopharma Ltd (NASDAQ: RDHL) just received an exclusive licence for the commercialisation of Talicia. The drug is used to treat Helicobacter Pylori infections, commonly known as H- Pylori. Talicia is a first-line therapy with commendable efficacy, tolerability, and drug resistance profile. It has the potential to replace other interventions against H. Pylori, making the biotech stock attractive.

The newly granted market exclusivity licence for Talicia comes with intellectual property protections. The IP protections will be in place until 2034. After the first three years, RedHill Biopharma may elect to allow other companies to market the product. The approvals and protections give RedHill Biopharma the first-mover advantage and other rights. Both will result in higher revenues.

‍

RedHill Biopharma is expected to rapidly commercialise the product. If that happens, the company will record rapid growth in revenues and profits. RedHill Biopharma now has the chance to emerge from the loss region. Buying the stock now would enable investors to benefit from the projected growth.

‍

Disclaimer: This content is made for entertainment purposes only. This is not financial advice.

‍